Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: jay silberman who wrote (126)	11/17/1997 5:40:00 PM
From: Charles Hill	Read Replies (1) \| Respond to of 656

I would be curious to know whether anyone has further insight into the sell reasoning given by the Montgomery analyst. All I have heard is positive stuff about the Enbrel results, a lot of it from people with a good grounding in molecular biology and medicine. The phase II and III studies certainly seemed to be well constructed and robust, so why the criticism? Are we missing something obvious here, or is this just another example of a poor call?